Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

550 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-07-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prevalence of participants who have protective immunity to measles virus is less than ninety percent.

Predictor of adequate measles antibody levels include the following :

* History of measles infection
* History of complete measles primary immunization( 2 doses with at least 1 month interval after age of 9 months)
* History of measles exposure

Predictor of inadequate measles antibody levels include the following :

* Born outside Thailand
* History of staying outside Thailand for long time in childhood
* Living in the rural area for a long period in childhood
* Fail to participate school system on time

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Second Dose of Measles Vaccine (MV) in the Second Year of Life

NCT02943681

Child Mortality Child Morbidity

COMPLETED NA

Non-Specific Effects of Standard Titre Measles Vaccination

NCT00168662

Measles

COMPLETED PHASE4

The Interaction Between Measles and DTP Vaccination

NCT02710045

Non-target Heterologous Effects of Vaccines Vaccine Interactions

COMPLETED NA

Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.

NCT01668745

Measles Vaccine

COMPLETED PHASE4

Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)

NCT05154097

Measles Vaccine

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Measles

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adequate antimeales antibody levels

ELISA test OD \> 0.1

No interventions assigned to this group

Inadequate measles antibody levels

ELISA test OD \< 0.1

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-30 years old

Exclusion Criteria

* Last measles vaccination less than 10 years of age
* Immunocompromised host including congenital immune defect, splenectomy or splenic dysfunction, history of suspect HIV exposure, taking immunosuppressant
* Receiving blood or blood product within 3 months
* Receiving others vaccinations or immunoglobulins or any medication that possibly decrease immune response

Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes